Enzymatica AB (publ)
Enzymatica AB (publ) is a biotechnology company focused on the development and commercialization of enzyme-based products for industrial applications, primarily in the pharmaceutical and biotechnology sectors.
Business. Enzymatica AB (publ) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange under the ticker symbol ENZY.ST. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Enzymatica AB (publ) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange under the ticker symbol ENZY.ST. Specific details regarding operating segments and geographic revenue mix are not available.
### Capital Structure and Liquidity Enzymatica maintains a strong liquidity position with SEK 33.13 million in cash and equivalents, representing 22.6% of total assets. The company's price-to-book ratio of 5.55 suggests a premium valuation relative to its tangible book value. Despite a negative operating income of SEK -51.37 million, the company's low debt-to-equity ratio of 0.01 indicates minimal leverage risk.
### Profitability and Returns Enzymatica's profitability metrics are underperforming relative to industry norms. The company reported a net loss of SEK -51.89 million, resulting in a negative return on equity of -41.79% and a return on assets of -36.55%. These figures fall significantly below the typical performance of pharmaceutical firms, which generally exhibit positive returns on equity and assets.
### Segments and Geographic Exposure The company's revenue is concentrated in a single business segment focused on enzyme-based products for industrial applications. Geographic exposure is not disclosed in the available data, but the company is headquartered in Sweden, suggesting a potential regional concentration risk.
### Growth Trajectory Enzymatica's revenue of SEK 53.90 million reflects a challenging operating environment, with a gross profit of SEK 33.13 million. The company's free cash flow of SEK -46.72 million indicates ongoing cash burn, which may constrain growth initiatives unless offset by new product launches or strategic partnerships.
### Risk Factors The company faces moderate liquidity risk due to its negative operating cash flow of SEK -40.97 million, but its strong cash reserves mitigate immediate concerns. Dilution risk is assessed as low, with no immediate filing-based flags detected. The company's capital expenditure of SEK -231,000 is minimal, suggesting a conservative approach to asset investment.
### Recent Events No recent filings or transcripts have been identified that would indicate significant changes in the company's strategic direction or financial health.
- Enzymatica maintains a strong liquidity position with SEK 33.13 million in cash and equivalents.
- The company's profitability metrics are underperforming, with a negative return on equity of -41.79%.
- Revenue is concentrated in a single business segment, potentially increasing exposure to market-specific risks.
- Free cash flow remains negative at SEK -46.72 million, indicating ongoing cash burn.
- The company's low debt-to-equity ratio of 0.01 suggests minimal leverage risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Enzymatica AB (publ) Market data — financials · 2026-05-27
- Enzymatica AB (publ) Market data — ESG · 2026-05-27